In Australia, there is a high incidence of melanoma, and until recently, the treatment and median overall survival for advanced metastatic melanoma had not changed in decades. The recognition of BRAF as an important tumour oncogene in melanoma has led to the development of targeted therapies, and in the last few years, we have seen the impact of these therapies, with significant improvement in response rate, duration of disease control and overall survival for patients with BRAF mutation-positive metastatic melanoma. Concurrently, the science of immunotherapy has evolved beyond the knowledge of the importance of the immune system in cancer, leading to the development of checkpoint inhibitors. The development of checkpoint inhibitors as a tolerable and effective therapy for metastatic melanoma, which has demonstrated improved response rates, duration of control and overall survival for patients, has implications beyond the care of patients with metastatic melanoma as these therapies are being trialled in other malignancies. This article will review the current standard of care and available therapies for metastatic malignant melanoma.
Introduction
Australia has one of the world's highest incidences of melanoma; it represents over 10% of new cancer diagnoses, and it is estimated that 1774 deaths will be attributed to metastatic melanoma in 2016. 1 Before 2010, there was less effective therapy for advanced melanoma. The diagnosis carried a dismal prognosis, with a median overall survival of 6-9 months and less than 20% chance of surviving for 2 years. 2 Palliative chemotherapy with dacarbazine was the standard of care for decades; however, a meta-analysis in 2007 found that a patient's chance of responding to this chemotherapy was only 15% without improving survival. 3 In the past few years, there has been a paradigm change in the management of advanced melanoma with the development of highly effective, targeted immunotherapies, which has revolutionised the management of patients.
This review article aims to summarise recent developments and discuss the implications of their use as well as the availability of therapy within the Australian prescribing environment.
Targeted therapy
The MAPK cellular pathway is essential for cell growth, division, differentiation, migration and apoptosis. BRAF and MEK proteins are consecutive steps in this pathway. In 2002, BRAF mutations were reported to occur frequently in 40-60% of patients with advanced melanoma, resulting in constitutive activation of BRAF. The most frequent mutations are V600E and K, and less common mutations include V600R and D. 4, 5 The discovery of the role of BRAF mutations led to the development of targeted inhibitors of BRAF protein, namely, vemurafenib and dabrafenib. Both of these therapies progressed rapidly through phase I-III clinical trials.
The initial publication of these trials in 2011 (vemurafenib vs dacarbazine) and 2012 (dabrafenib vs dacarbazine) demonstrated consistent results, with single-agent BRAF inhibitors showing an excellent response rate of approximately 50%; however, the duration of response was short lived, with a median duration of control of 6-7 months. 6, 7 In 2012, it was reported that the response rates and duration of control could be improved with the addition of trametinib (a MEK inhibitor) to dabrafenib.
The years 2012 and 2013 saw the opening of two phase III dabrafenib and trametinib combination therapy trials and a vemurafenib and cobimetinib (MEK inhibitor) combination trial. By the end of 2014, the progression-free survival results of all these trials were reported, demonstrating a significant improvement in progression-free results, with overall survival reported in 2015. [9] [10] [11] Subsequently, combination therapy with BRAF and MEK inhibitors became a worldwide standard of care for BRAF mutation-positive advanced or unresectable melanoma (Table 1) .
Dabrafenib was reimbursed for Australian patients with advanced melanoma with an activating V600 mutation in December 2013 as first-line therapy with trametinib was reimbursed for combination therapy in patients who were on dabrafenib in August 2015. The Pharmaceutical Benefits Scheme (PBS) lists the cost of dabrafenib per month as AU $8760 and the cost of trametinib per month as AU $8760.
Since the discovery of BRAF, other activating mutations have been described, including c-kit and NRAS mutation. C-kit is more frequently present in mucosal, acral and melanoma associated with chronic sun damage. 12 However, clinical trials with therapies against c-kit have only demonstrated modest and short-lived responses with a duration of 3-4 months. 13 NRAS mutations occur in approximately 20% of patients and can be targeted by MEK inhibitors. A recent phase III trial compared a MEK inhibitor (binimetinib) to dacarbazine and was presented in 2016. This demonstrated modest response rates (15%) and duration of control, 2.8 months compared to 1.5 months for dacarbazine. There is currently no reimbursed access to targeted therapy against c-kit-or NRAS-mutated melanoma, and these therapies have little relevance in the context of the recent progress with immunotherapy. 14, 15 Immune therapy
The importance of the immune system in the control of melanoma has been widely known, with spontaneous regression of biopsy-proven metastatic melanoma first reported in the mid 1800s.
Research into utilising the immune system to target melanoma dates back to the 1960s; however, despite decades of research into the immune system, there was no improvement in overall survival until 2010 when Hodi et al. reported on the overall survival benefit with ipilimumab in the second-line setting. 16 Ipilimumab is a fully human monoclonal IgG1 antibody that blocks cytotoxic T cell lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 downregulates the pathway of T cell activation. 16 The first reported trial was in second-line patients, demonstrating that ipilimumab 3 mg/kg with or without the gp100 vaccine improved overall survival in patients compared with gp100 alone. 16 This trial was met with reservations at the time of publication as the control arm used the gp100 vaccine as opposed to a placebo. However, these data were supported by a confirmatory trial published in 2011 where ipilimumab 10 mg/kg and dacarbazine was compared to dacarbazine in untreated patients with advanced melanoma. 17 This demonstrated no evidence of increased efficacy at the 10 mg/kg dosing but reported an increase in hepatotoxicity with the addition of dacarbazine. As such, the approved indication for ipilimumab is at 3 mg/kg as monotherapy.
These trials supported the use of ipilimumab in both first-and second-line therapy for advanced melanoma. Unique immune-related adverse events and the need for strict management algorithms were also recognised as requiring management for patient safety ( Table 2) . Ipilimumab has been reimbursed in Australia as monotherapy at 3 mg/ kg for four doses since August 2013. Patients may be re-induced for four more doses if they initially responded to therapy. The PBS listed cost of ipilimumab for a 75 kg patient is AU$ 29 610 per dose.
The field of immune therapy subsequently moved quickly with the rapid development of programmed cell death (PD-1)-based therapy.
PD-1 is an inhibitory receptor expressed by T cells, preferentially with long-term exposure to antigens. Its primary ligand PD-L1 is frequently expressed within the tumour microenvironment. The PD-1 receptor also binds to PD-L2, which is preferentially expressed on antigenpresenting cells. 18 The proposed mechanism of action of PD-1 antibodies is by blocking the interaction between PD-1 and PD-L1; it releases the cytotoxic function of tumour-specific T cells. 18 Nivolumab, a fully humanised IgG4-blocking monoclonal antibody directed against PD-1, was first reported in a phase I trial against solid tumours in 2012. In this large phase I trial, 104 melanoma patients were enrolled, with an encouraging response rate of 41% in the 3 mg/ kg arm. 19 Given these results, trials looking at nivolumab in both treated and untreated melanoma were developed and rapidly accrued in 2013.
In the same year, a phase I trial of pembrolizumab (then known as lambrolizumab), a highly selective humanised monoclonal IgG4Kappa antibody against PD-1, was initially reported; 135 melanoma patients demonstrated a response rate of 38%. 18 This phase 1 trial was rapidly expanded into what became known as KEYNOTE 001, and randomised phase II and III trials of pembrolizumab completed recruitment early in 2014.
In late 2014 and early 2015, the phase III trials of both nivolumab and pembrolizumab in untreated metastatic melanoma were reported.
Nivolumab in untreated BRAF wild-type advanced melanoma (CheckMate 066) was reported in November 2014, comparing nivolumab 3 mg/kg with dacarbazine. This blinded controlled trial of 418 patients initially reported response rates of 40% compared to 13.9%, and overall survival at 1 year was 72.9% versus 42.1%, respectively; these results of the interim analysis led to patients being unblinded and allowed to cross over. Checkmate 066 also demonstrated the tolerability of nivolumab, with only 6.8% patients discontinuing therapy due to adverse events. 20 Only 5 months later, the phase III trial of pembrolizumab versus ipilimumab (KEYNOTE 006) in advanced melanoma was reported, confirming the benefit of anti PD-1 therapy. This unblinded, controlled trial randomised 834 patients 1:1:1 to pembrolizumab at 10 mg/kg every 2 or 3 weeks for 2 years versus ipilimumab at 3 mg/kg. During first analysis, this trial demonstrated a significantly improved 1-year overall survival of 74% (10 mg/kg every 2 weeks), and 68% (10 mg/kg every 3 weeks) versus 58% for ipilimumab and patients on the ipilimumab arm, respectively, were allowed to cross over. The response rates were similar to those seen in the phase I trials of 33.7 and 32.9% versus 11.9%. The rates of discontinuation due to adverse events were 4 and 6.9% versus 9.4% respectively (Table 3) . 21 KEYNOTE 006, unlike the Checkmate066, allowed BRAF mutation-positive patients to be enrolled; 302 patients who were BRAF positive were enrolled equally across all three arms, and around 50% of these patients had previously been exposed to a BRAF or MEK inhibitor.
While the numbers are small (151 in all arms who had previous treatment with BRAF inhibition), there is a suggestion that patients have a better outcome without previous targeted therapy. 21 There is currently a trial recruiting participants overseas, which is aiming to answer the question of optimal sequencing of targeted versus immune therapy.
Both pembrolizumab and nivolumab have been trialled in previously treated patients, with results published in 2015.
In CheckMate 037, 405 patients were randomised 2:1 to nivolumab or investigator's choice of chemotherapy. In this trial, of the 133 patients randomised to chemotherapy, 31 patients withdrew consent after randomisation to the chemotherapy arm. This was a heavily pretreated group of patients, with almost 100% of patients in both arms being exposed to ipilimumab, 17-18% exposed to a BRAF inhibitor and 53-54% to chemotherapy. The response rate for nivolumab was 31.7 and 5% for chemotherapy. 22 The trial was reported in 2015 when it met its primary end-point of objective response rate and was updated in 2016 when it reported overall survival. The overall survival was not statistically different between the two arms, 15.7 months for nivolumab and 14.4 for chemotherapy. 23 These results, however, have been impacted by the crossover of patients from chemotherapy to compassionate use PD-1-based therapy, which has been widely available since 2014. KEYNOTE 002 was also reported in 2015. This trial randomised 540 ipilimumab refractory patients (defined by confirmed disease progression within 24 weeks of the last dose of ipilimumab) to either 2 mg/kg or 10 mg/kg pembrolizumab or chemotherapy. The majority of patients had been exposed to two or more therapies, with 100% patients using ipilimumab, 46-50% of patients undergoing chemotherapy and 24-26% of patients receiving a BRAF or MEK inhibitor. Radiological response was seen in 21% (2 mg/kg) and 25% (10 mg/ kg) versus 4% in the chemotherapy arm, with progression-free survival improving from 3.6 months with chemotherapy to 5.4 months (2 mg/kg) and 5.8 months (10 mg/kg). 24 This trial was updated in 2016 and confirmed an improvement in overall survival for both pembrolizumab arms. 25 The combined analysis of the various dosing schedules in KEYNOTE 001, 002 and 006 demonstrated no significant difference in response or survival, and as such, the dosing schedule for advanced disease that has been approved for pembrolizumab is 2 mg/kg every 3 weeks.
Within a 6-month period, the publication of these large trials demonstrating significant improvements in both disease control and overall survival led a rapid change of practice whereby PD-1 monotherapy became a standard of care worldwide.
Pembrolizumab has been reimbursed in Australia since September 2015 as first-line therapy for patients with advanced melanoma without activating BRAF mutation and second-line therapy for those with a BRAF mutation after progression on intolerance on targeted therapy. For a 75-kg patient, the PBS-listed cost of pembrolizumab is AU $6792, excluding the cost of the infusion suite admission and associated cost. Nivolumab was given a similar reimbursement indication in May 2016, and the cost for a patient of similar weight is AU$ 8121.
Given the advances in metastatic disease both nivolumab and pembrolizumab have been trialled in the adjuvant setting; these trials have completed recruitment in 2015 and 2016, and we expect the results in years to come.
Pseudo-progression
With the advent of immunotherapy, the methods used to assess disease response needed to be adapted. Historically, the presence of a new lesion or >20% increase in the size of known disease was defined as progression. Pseudo-progression is thought to occur when immune therapy causes a pronounced immune infiltrate in tumours. This can increase the size of existing lesions or the apparent development of new lesions at the first radiological assessment. Over repeated imaging, there is a subsequent reduction in tumour size. 26 In Checkmate 066, where treatment beyond progression was allowed, it was noted that 8.1% of the patients who received nivolumab and had formally progressed subsequently went on to have a 30% or more reduction in tumour burden. 20 This was the first phase III trial to capture 'pseudo-progression' with immunotherapy in a prospective fashion.
KEYNOTE 006 did not allow treatment beyond progression. Tumours were assessed, and if progression was noted and confirmed on a follow-up scan 4-6 weeks later, patients were discontinued from study; as such, we do not have a rate of pseudo-progression from this phase III trial. 21 In retrospective analyses with pembrolizumab, the incidence of pseudo-progression is reported to be between 6.7 and 12%. 26 While the incidence of pseudo-progression is relatively low, it occurs in clinical practice, and the difficulty for clinicians is differentiating between pseudo-progression and progressive disease, necessitating a change therapy.
Combination immunotherapy
During the development of immunotherapy, it was recognised that the CTLA-4 blockade and PD-1 blockade had roles that were complementary in controlling the immune response to tumour; as such, a phase I combination trial was developed and reported in 2013. In this dose-finding and safety trial, where 86 patients with advanced melanoma were reported on, 53 patients received concurrent therapy and 33 sequential therapy. The incidence rate of the Grade 3-4 adverse events was noted to be 53%, including pruritus, hepatitis, fatigue and rash; 21% of patients discontinued due to adverse events.
This trial noted reductions in tumour volume of more than 80% on some patients, which had not been previously noted in immunotherapy trials. The clinical benefit rate was 65% (complete and partial response and stable disease). 27 The results of this trial, which at the time were ground breaking for immune therapy, led to the design of Checkmate 067, which was a randomised, phase III, double blind trial of 945 untreated advanced melanoma patients on ipilimumab (3 mg/kg) alone, nivolumab (3 mg/kg) alone or combination nivolumab (1 mg/kg) and ipilimumab (3 mg/kg) each for 12 weeks. Patients randomised to either nivolumab arm then continued on nivolumab fortnightly until progression or unacceptable adverse events. This trial was powered to demonstrate that the two nivolumab-containing arms were superior to ipilimumab monotherapy. Recruitment to this trial was rapid, and the progression-free survival results were initially published in 2015, but overall survival has not yet been reported. 28 The results demonstrated a response rate of 19% for ipilimumab, 43.7% for nivolumab and 57.7% for combination therapy, with an improvement in PFS for both nivolumab arms of 6.9 and 11.5 months (combination), respectively, compared with 2.9 months for ipilimumab.
Checkmate 067 confirmed the adverse events rate seen in the phase 1 trial, with 55% of patients in the combination arm experiencing G3/4 adverse events, the most common being colitis, hepatitis and diarrhoea; 36.4% of patients in the combination arm ceased therapy because of adverse events compared with 7.7% in the nivolumab arm and 14.8% in the ipilimumab arm. 28 The toxicities of Checkmate 067 led to the development of KEYNOTE 029, a phase 1b trial with the aim of reducing the dose of ipilimumab to 1 mg/kg while maintaining dose intensity of PD-1 blockade (pembrolizumab 2 mg/kg); the intention was that by doing this, responses would be maintained, with a lower rate of adverse events.
KEYNOTE 029 was reported in late 2015, demonstrating in 153 melanoma patients that the lower dose of ipilimumab was more tolerable, with only 10% of patients ceasing due to adverse events and a 25% incidence of G3-4 immune-related adverse events ( Table 4 ). The response rate was strikingly similar to Checkmate 067 at 57%. 29 There is currently a larger randomised phase III trial underway looking at the two dosing schedules of nivolumab 1 mg/kg and ipilimumab 3 mg/kg versus nivolumab 3 mg/kg and ipilimumab 1 mg/kg to see if using the lower dose of ipilimumab will maintain response with less toxicity.
Biomarkers
Recent trials have looked for biomarkers for the prediction of response to immune therapy given the mechanism of action of PD-1 antibodies; PD-L1 has been assessed as a biomarker and was a stratification factor for all of the phase III trials.
In Bristol Myers Squibb trials, PD-L1 positivity has been defined by use of an immunohistochemical assay, with at least 5% of tumour staining positive within 100 tumour cells. 20, 28 In Checkmate 066, PD-L1 positivity was prognostic of improved survival regardless of treatment arm, compared with PD-L1-negative patients. In the PD-L1-negative arm, survival and response (33.1% vs 15.7%) was better with nivolumab compared with dacarbazine, and as such, PD-L1 could not be used as a biomarker to select patients who should not receive nivolumab. 20 Checkmate 067 demonstrated that PD-L1-positive patients had response and progression-free survival on mono-or combination therapy; however, the PD-L1-negative patients who received combination therapy appeared to do better. 28 However, this must be interpreted within the context that this trial was not powered to show a difference between the two nivolumab-containing arms, and as such, it is difficult to state confidently that PD-L1-negative patients should have combination therapy. However, this may be a factor in selecting who to offer combination therapy if this is confirmed in subsequent trials.
In KEYNOTE 006, sponsored by Merck Sharpe and Dohme, a PD-L1-positive result was defined by positive staining of 1% of tumour and cells; in this trial, benefit was seen within both the PD-L1-positive and -negative arms as evident by the similar hazard ratios (0.55 and 0.58) for benefit. However, given the lower rate of PD-L1-negative patients (20%) with the lower threshold for a positive result at 1%, it is difficult to draw a firm conclusion on the utility of testing for PD-L1 as a biomarker for melanoma from this trial. 21 
Future perspective
In the last 5 years, significant advances in response rates, progression-free and overall survival have been made for patients with advanced melanoma; however, there is still progress that needs to be made.
Research is needed to increase the efficacy of immunotherapy while reducing the toxicity rates currently associated with combination therapy. There are currently phase III trials underway looking at combining PD-1-based therapy with attenuated viral therapies, indoleamine 2,3-dioxygenase (IDO) inhibitors, which may further progress in this arena by increasing the response rate of single-agent PD-1 antibodies without increasing the adverse events. A clinically validated and reliable biomarker for the prediction of benefit for combination immunotherapy is needed given the current toxicities of therapy and the costs involved in these treatments.
While the current data potentially suggest that PD-L1 may be useful in helping to select who would benefit most from a CTLA-4 antibody, we await the overall survival results from Checkmate 067 and confirmatory trials. The currently available data would suggest that we cannot use PD-L1 negativity as a biomarker to deny a patient's access to PD-1-based monotherapy as there is still a survival benefit for patients when given PD-1 antibodies.
While it is understood that pseudo-progression occurs, we cannot determine this in an individual patient, and the ability to predict response would be practice changing. Currently, in clinical practice, when the first assessment of disease is made, there are no methods to predict progressive disease, as opposed to pseudo-progression. This is obviously associated with not insignificant distress for patients as they wait for the next set of imaging to see if their tumour growth has stabilised or decreased. It is only after two sets of imaging demonstrating progression that we as clinicians feel able to recommend a change in therapy (this is partly dictated by the reimbursement for PD-1-based therapy in Australia, where the PBS dictates that patients cannot be re-challenged by PD-1-based therapy after receiving ipilimumab).
The PBS restrictions on prescribing also need to be taken into account for both BRAF mutation-positive and wild type patients before initiating treatment of Australian patients as the PBS dictates what can be offered to our patients and when should they wish to access reimbursed therapy.
In adjuvant therapy arenas, both dabrafenib and trametinib as combination therapy, vemurafenib monotherapy and immunotherapy have been trialled in resected Stage III and IV disease. The results of these trials will likely change our management of adjuvant therapy for melanoma when the results are available in the next few years as there is no accepted current systemic standard of care for adjuvant therapy for melanoma in Australia. 
Conclusion
The current treatment landscape for advanced melanoma has changed rapidly in the last few years, and there are now several different classes of therapy that can be offered to patients depending on their mutational status and disease burden (Fig. 1) . However, there is still a need for improvement, and as such, ongoing patient enrolment and participation in clinical trials is vitally important for us to be able to offer our patients improved response rates and long-term disease control either to 'cure' patients or turn advanced melanoma into a 'chronic' disease.
